spacer
home > pmps > autumn 2008 > universal clarity
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Universal Clarity

People with a visual impairment often experience problems in differentiating packets, with the increased standardisation of packaging sizes and shapes. They can also have problems with reading the instructions since they are often printed in a small typeface with poor visual quality. In order to alleviate these problems, the European Commission has issued a directive requiring suppliers of pharmaceutical products to incorporate braille labels and produce information leaflets in alternative formats. However, the associated standard has yet to be published, which leaves uncertainty about the detailed implementation of the directive.

Packaging poses significant problems for many older people. This is often due to an inability to read the label, understand its meaning or open the package without damaging the contents. Failure to take medicine correctly has been estimated to cost the US economy $100 billion per year (1).

THE VISUALLY IMPAIRED POPULATION

About 1.5 per cent of the population could be officially registered as ‘blind’ or ‘partially sighted’. Of these, around 0.4 per cent have to rely on non-visual methods to access information (2)...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr John Gill, OBE DSc FIET, is Chief Scientist at RNIB in the UK. He has worked for over 35 years in the area of scientific and technological research for people with disabilities. His research has included the design of fonts, public access terminals, tactile communication, orientation systems, automated production of braille and large print, smart card and biometric systems, and accessibility of information and communication technology systems and services. He has visited over 40 countries and written over 200 publications.
spacer
Dr John Gill
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Arcis Biotechnology appointments Professor Steve Howell as Non-Executive Chairman

Daresbury, UK, 24 July 2019: Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced it has appointed Professor Steve Howell as Non-Executive Chairman of its Board of Directors. Steve takes over the position from Paul Foulger, who was serving as Chairman on an interim basis on behalf of the Board.
More info >>

White Papers

Wrap Around Label - A Lot of Content in a Small Space

Faubel & Co. Nachfolger GmbH

One of the world’s largest contract research organizations for the planning and conducting of clinical trials was faced with the challenge of accommodating many different national languages on an inhaler. The inhaler was then to be distributed in 47 countries. Due to the impressive quality and reliable collaboration, the organization commissioned Faubel with finding the optimal labeling solution for the inhaler.
More info >>

 
Industry Events

SMi Presents the 4th Annual: Highly Potent Active Pharmaceutical Ingredients (HPAPI)

11-13 May 2020, Copthorne Tara Hotel, London, UK

SMi is delighted to announce its 4th Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 11th – 12th May 2020. HPAPI 2020 conference focuses on the growing landscape driven by the demand for highly potent drugs in oncology, diabetes and autoimmune disease treatment. This event will address the biggest challenges the industry is facing with regards to determining toxicology limits, assessing hazards, implementing risk procures, translating risk assessment into facility engineering, preventing and dealing with cross-contamination and adhering to GMP regulatory guidelines.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement